Property | Value |
Name | Histone deacetylase enzyme inhibitors and possible use in therapeutics |
Description | Review article:-Pharmacology Vasantha M N, S Kannan, Ayesha Sulthana, Nidhi Tyagi & Manoj G Tyagi* Department of Pharmacology, Christian Medical College, Vellore 632002, India
Abstract:- Histone deacetylases (HDACs) enzymes modify the acetylation status of histone proteins and other critical cellular proteins and are recognized as potentially useful therapeutic targets for a broad range of human disorders. Pharmacological interventions using small-molecule HDAC inhibitors may restore transcriptional balance to neurons, modulate cytoskeletal function, and affect immune responses and enhance protein degradation pathways. These have been found to beneficial in various experimental models of disease. In this review article we elaborate on the mechanism of HDAC enzymes in modifying various disease states and reflect on some new prototype drugs introduced for the treatment of some clinical manifestations.
Key words:- HDAC, enzymes, DNA, cell cycle, acetyl transferases, T cells.
References:- 1.Anna Portela and Manel Esteller. Epigenetic modifications and human disease.Nature Biotechnology,October 2010,vol 28:1057-1066. 2.Allexander Link,Francesc Balaguer, Ajay Goel.Cancer chemoprevention by dietary polyphenols:Promising role for epigenetics. Biochemical Pharmacology 2010; 80:1771-92. 3.Lasse Sommer Kristensen, Helene Myrtue Nielsen and Lise Lotte Hansen.Epigenetics and cancer treatment.Institute of human genetics ,2009. 4.Jonathan D.Best and Nessa Carey. Epigenetic therapies for non-oncology indications.Drug Discovery Today,December 2010,vol 15:1008-1013. 5.Carolyn Ptak and Arturas Petronis.Epigenetics and Complex Disease:From Etiology to new Therapeutics.The Annual Review of Pharmacology and Toxicology 2008;48:10.1-10.20. 6.Claude Monneret. Histone deacetylase inhibitors. European Journal of Medicinal Chemistry 2005;40:1-13. 7.Eric Hahnen, Jan Hauke, Christian Trankle, Ilker Y Eyupoglu, Brunhilde Wirth and Ingmar Blumcke. Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert opin. Investig. Drugs, 2008; 17:1-16. 8.Angela Nebbiso, Fabio Manzo, Marco Miceli, Mariarosaria Conte, Lucrezia Manente, Alfonso Baldi, Antonio De Luca, Dante Rotili, Sergio Valente, Antonello Mai, Alessandro Usiello, Hirich Gronemeyer and Lucia Altucci. European Molecular Organisation reports, 2009; 10:776-81. 9.Cassadra Willyard and Brooklyn. The saving switch. Nature medicine 2010; 16:18-21. 10.De-Maw Chuang,Yan Leng, Zoya marinova,Hyeon-Ju Kim and Chi-Tso Chiu.Multiple roles of HDAC inhibition in neurodegenerative conditions.Trends in neurosciences,September 2009;32:591-9. 11.Gregoretti IV,Lee YM,Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17 – 31. 12.Marks PA,Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 2007;25: 84 – 90. 13.Dokmanovic M,Marks PA. Prospects: histone deacetylase inhibitors. J CellBiochem 2005;96:293 – 304. 14.Minucci S,Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6: 38 – 51. 15.Rosato RR,Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005;9:809 – 24. 16.Xu W,Parmigiani R,PA M. Histone deacetylase inhibitors: molecular mechanism of action. Oncogene 2007;26:5541 – 52. 17.Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev 2001;11:162–6. 18.Wang AH, Yang XJ. Histone deacetylase 4 possesses intrinsic nuclear import and export signals. Mol Cell Biol 2001;21:5992–6005. 19.Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG. Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 2008;65: 4000–18. 20.Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009;460:587–91. 21.Anekonda TS, Reddy PH. Neuronal protection by sirtuins in Alzheimer’s disease. J Neurochem 2006;96:305–13. 22.Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of nonhistone proteins. Gene 2005;363:15–23. 23.Spange S, Wagner T, Heinzel T, Kramer OH. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 2009;41:185–98. 24.Chuang DM, Leng Y, Marinova Z, Kim HJ, Chiu CT. Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci 2009;32:591–601. 25.Pearce EL, Shen H. Making sense of inflammation, epigenetics, and memory CD8+ T-cell differentiation in the context of infection. Immunol Rev 2006;211:197–202. 26.Gray SG, Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006;1:67–75. 27.Reddy P, Maeda Y, Hotary K, Liu C, Reznikov LL, Dinarello CA, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graftversus- host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004;101:3921–6. 28.Tao R, de Zoeten EF, Ozkaynak E, Chen C, Wang L, Porrett PM, et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007;13:1299–307. 29.Moreira JM, Scheipers P, Sorensen P. The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses. BMC Cancer 2003;3:30. 30.Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57 69. 31.Faraco G, Pittelli M, Cavone L, Fossati S, Porcu M, Mascagni P, et al. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis 2009;36:269–79. 32.Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 2003;87:407–16. 33.Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 2007;68:S43–54 (discussion S22–31). 34.Marin-Husstege M, Muggironi M, Liu A, Casaccia-Bonnefil P. Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J Neurosci 2002;22:10333–45. 35.Shen S, Liu A, Li J, Wolubah C, Casaccia-Bonnefil P. Epigenetic memory loss in aging oligodendrocytes in the corpus callosum. Neurobiol Aging 2008;29:452–63. 36.Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, et al. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 2008;11:1024–34. 37.Ren, M. et al. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem2004;89, 1358–67. 38.Kim, H.J. et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J. Pharmacol. Exp 2007; Ther. 321, 892–901. 39.Faraco, G. et al.Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol 2006; 70, 1876–84. 40.Subbanna PK, Tyagi MG.PAF antagonism modifies neuroprotective action of histone deacetylase and calcineurin phosphatase inhibitors in mice. Indian J Exp Biol. 2006 Nov;44(11):886-91. 41.Hodges, A. et al. Regional and cellular gene expression changes in human Huntington’s disease brain. Hum. Mol. Genet 2006;15, 965–77. 42.Sugars, K.L. and Rubinsztein, D.C. Transcriptional abnormalities in Huntington disease. Trends Genet 2003; 19, 233–8. 43.Airaksinen, M.S. and Saarma, M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci 2002; 3, 383–94. 44.Kontopoulos, E. et al. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum. Mol. Genet 2006; 15, 3012–23. 45.S. Akbarian, et al., Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia, Arch. Gen. Psychiatry 2005;62 (8) :829–40. 46.D.P. Gavin, et al., Histone deacetylase inhibitors and candidate gene expression: an in vivo and in vitro approach to studying chromatin remodeling in a clinical population, J. Psychiatr. Res 2009; 43 (9) 870–6. 47.D.P. Gavin, et al., Reduced baseline acetylated histone 3 levels, and a blunted response to HDAC inhibition in lymphocyte cultures from schizophrenia subjects, Schizophr. Res 2008;103 (1–3) :330–2. 48.H.S. Huang, et al., Chromatin immunoprecipitation in postmortem brain, J. Neurosci. Methods 2006;156 (1–2):284–92. 49.F. Stadler, et al., Histone methylation at gene promoters is associated with developmental regulation and region-specific expression of ionotropic and metabotropic glutamate receptors in human brain, J. Neurochem 2005; 94 (2): 324–36. 50.Matevossian, S. Akbarian, A chromatin assay for human brain tissue, J. Vis. Exp. (13) (2008). 51.S. Al-Mahdawi, et al., The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues, Hum. Mol. Genet 2008; 17 (5) : 735–46. 52.D.P. Gavin, et al., Histone deacetylase inhibitors and candidate gene expression: an in vivo and in vitro approach to studying chromatin remodeling in a clinical population, J. Psychiatr. Res 2009; 43 (9) :870–6. 53.H.S. Huang, et al., Prefrontal dysfunction in schizophrenia involves mixed lineage leukemia 1-regulated histone methylation at GABAergic gene promoters, J. Neurosci 2007; 27 (42):11254–62. 54.H.S. Huang, S. Akbarian, GAD1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia, PLoS ONE 2 (57) N. Mellios, et al., Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia, Biol. Psychiatry 65 (12) (2008) 1006–1014. (8) (2007) e809. 55.S. Akbarian, et al., Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia, Arch. Gen. Psychiatry 2005;62 (8):82. 56.S. Akbarian, H.S. Huang, Epigenetic regulation in human brain-focus on histone lysine methylation, Biol. Psychiatry 2009; 65 (3): 1. 57.S.L. Berger, The complex language of chromatin regulation during transcription, Nature 2007;447 (7143): 407–41298–203. 58.T. Kouzarides, Histone methylation in transcriptional control, Curr. Opin. Genet. Dev. 12 (2) (2002) 198–209. Neurosci. Methods 156 (1–2) (2006) 284–292.9–840. 59.Dai, J. et al. Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J. Virol 2009;83, 4528–37. 60.Siliciano, J.D. et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med 2003; 9, 727–8. 61.Blazkova, J. et al. CpG methylation controls reactivation of HIV from latency. PLoS Pathog 2009; 5, e100554 62.Cervoni, N. and Szyf, M. Demethylase activity is directed by histone acetylation. J. Biol. Chem 2001;276: 40778–87. 63.Redel L. et al. HIV-1 regulation of latency in the monocyte macrophage lineage and in CD4+ T lymphocytes. J. Leukoc. Biol. Oct 2.[Epub ahead of print] Turner, B. M. Cellular memory and the histone code. Cell 2009;111, 285–91. 64. Mosley, A. L. & Ozcan, S. Glucose regulates insulin gene transcription by hyperacetylation of histone h4. J. Biol. Chem 2003 ;278, 19660–6 . 65.Mosley, A. L., Corbett, J. A. & Ozcan, S. Glucose regulation of insulin gene expression requires the recruitment of p300 by the beta-cell-specific transcription factor Pdx-1. Mol. Endocrinol 2004; 18, 2279–90 . 66.Mosley, A. L. & Ozcan, S. The pancreatic duodenal homeobox-1 protein (Pdx-1) interacts with histone deacetylases Hdac-1 and Hdac-2 on low levels of glucose. J. Biol. Chem 2004; 279, 54241–7. 67.Qing, H. et al. Valproic acid inhibits Ab production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J. Exp. Med.2008; 205, 2781–9. 68.Belayev, N. D. et al. Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease. EMBO Rep 2009; 10, 94–100. 69.Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR.Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007 Jan 1;109(1):31-9. Epub 2006 Sep 7. 70.Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769–84. 71.Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE.Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009 Nov 10;27(32):5410-7.
Copyright © 2013 Tyagi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
Filename | Tyagi et al. (416-424).pdf |
Filesize | 459.23 kB |
Filetype | pdf (Mime Type: application/pdf) |
Creator | admin |
Created On: | 01/05/2013 00:00 |
Viewers | Everybody |
Maintained by | Editor |
Hits | 2145 Hits |
Last updated on | 02/18/2013 17:40 |
Homepage | |
CRC Checksum | |
MD5 Checksum |